GYRE Long Call Strategy
GYRE (Gyre Therapeutics, Inc.), in the Healthcare sector, (Biotechnology industry), listed on NASDAQ.
Gyre Therapeutics, Inc., a pharmaceutical company, engages in the development and commercialization of small-molecule, anti-inflammatory, and anti-fibrotic drugs targeting organ fibrosis. It offers ETUARY (Pirfenidone), an anti-fibrotic drug approved for the treatment of idiopathic pulmonary fibrosis; and under phase 3 studies for dermatomyositis and systemic sclerosis-associated interstitial lung disease, pneumoconiosis, and diabetic kidney disease. The company is also involved the development of F351 (Hydronidone), a structural derivative of ETUARY (Pirfenidone), under Phase 3 studies for the treatment of chronic hepatitis B liver fibrosis; and under Phase 1 studies for liver fibrosis associated with nonalcoholic associated steatohepatitis. In addition, its development pipeline includes F573, under Phase 2 studies for the treatment of acute/acute-on-chronic liver failure; F528, under preclinical stage for the treatment of chronic obstructive pulmonary disease; and F230, under preclinical stage for the treatment of pulmonary arterial hypertension. The company was founded in 2002 and is headquartered in San Diego, California. Gyre Therapeutics, Inc. operates as a subsidiary of GNI USA, Inc.
GYRE (Gyre Therapeutics, Inc.) trades in the Healthcare sector, specifically Biotechnology, with a market capitalization of approximately $706.1M, a beta of 5.28 versus the broader market, a 52-week range of 6.57-11.67, average daily share volume of 98K, a public-listing history dating back to 2006, approximately 579 full-time employees. These structural characteristics shape how GYRE stock options price implied volatility around earnings windows, capital events, and macro-driven sector rotations.
A beta of 5.28 indicates GYRE has historically moved more than the broader market, amplifying both the directional payoff and the realized volatility relative to an index-equivalent position.
What is a long call on GYRE?
A long call buys upside exposure with a fixed maximum loss equal to the premium paid; profit accrues if the underlying closes above the strike plus premium at expiration.
Current GYRE snapshot
As of May 15, 2026, spot at $6.62, ATM IV 319.80%, IV rank 63.64%, expected move 91.68%. The long call on GYRE below is built from the same end-of-day chain, with strikes snapped to listed contracts and premiums pulled from the bid/ask midpoint at a 34-day expiry.
Why this long call structure on GYRE specifically: GYRE IV at 319.80% is mid-range versus its 1-year history, so strategy selection should anchor more to the directional thesis than to the IV regime, with a market-implied 1-standard-deviation move of approximately 91.68% (roughly $6.07 on the underlying). The 34-day window matched to the front-month expiry keeps theta exposure bounded while still capturing the post-snapshot move; longer-dated GYRE expiries trade a higher absolute premium for lower per-day decay. Position sizing on GYRE should anchor to the underlying notional of $6.62 per share and to the trader's directional view on GYRE stock.
GYRE long call setup
The GYRE long call below is built from the end-of-day chain, with each option leg priced at the bid/ask midpoint of its listed strike. With GYRE near $6.62, the first option leg uses a $6.62 strike; additional legs (when the strategy has them) anchor to spot-relative offsets. Premiums come from the bid/ask midpoint on the listed GYRE chain at a 34-day expiry; the cross-strike IV skew is reflected directly in the per-leg values rather than approximated. Quantity sizing assumes one contract per option leg (or 100 GYRE shares for the stock leg in covered calls and collars).
| Action | Type | Strike / Basis | Premium (est) |
|---|---|---|---|
| Buy 1 | Call | $6.62 | N/A |
GYRE long call risk and reward
- Net Premium / Debit
- N/A
- Max Profit (per contract)
- Unbounded
- Max Loss (per contract)
- Unbounded
- Breakeven(s)
- None on modeled curve
- Risk / Reward Ratio
- N/A
Max profit is unbounded; max loss equals the premium paid times 100. Breakeven is strike plus premium.
GYRE long call payoff curve
Modeled P&L at expiration across a range of underlying prices for the long call on GYRE. Each row is one sampled price point from the computed payoff curve; the full curve uses 200 price points internally before being summarized into 10 rows here.
When traders use long call on GYRE
Long calls on GYRE express a bullish thesis with defined risk; traders use them ahead of GYRE catalysts (earnings, product launches, macro events) when the expected upside justifies the premium and theta decay.
GYRE thesis for this long call
The market-implied 1-standard-deviation range for GYRE extends from approximately $0.55 on the downside to $12.69 on the upside. A GYRE long call expresses a directional view that the underlying closes above the strike plus premium at expiration, ideally with implied volatility holding or expanding to preserve extrinsic value through the hold period. Current GYRE IV rank near 63.64% is mid-range against its 1-year distribution, so the IV signal is neutral; the long call thesis on GYRE should anchor more to the directional view and the expected-move geometry. As a Healthcare name, GYRE options can move on sector-level news flow (peer earnings, regulatory updates, industry-specific macro data) in addition to GYRE-specific events.
GYRE long call positions are structurally bullish; the modeled P&L assumes European-style exercise at expiration and ignores early assignment, transaction costs, dividends paid before expiry on the stock leg (when present), and the bid-ask spread on the listed chain. GYRE positions also carry Healthcare sector concentration risk; news flow inside the sector (peer earnings, regulatory shifts, supply-chain headlines) can move GYRE alongside the broader basket even when GYRE-specific fundamentals are unchanged. Long-premium structures like a long call on GYRE are particularly exposed to IV-crush risk through scheduled events (earnings, FDA decisions, central-bank meetings) where IV typically contracts post-event regardless of the directional outcome. Always rebuild the position from current GYRE chain quotes before placing a trade.
Frequently asked questions
- What is a long call on GYRE?
- A long call on GYRE is the long call strategy applied to GYRE (stock). The strategy is structurally bullish: A long call buys upside exposure with a fixed maximum loss equal to the premium paid; profit accrues if the underlying closes above the strike plus premium at expiration. With GYRE stock trading near $6.62, the strikes shown on this page are snapped to the nearest listed GYRE chain strike and the premiums come straight from the end-of-day bid/ask midpoint.
- How are GYRE long call max profit and max loss calculated?
- Max profit is unbounded; max loss equals the premium paid times 100. Breakeven is strike plus premium. For the GYRE long call priced from the end-of-day chain at a 30-day expiry (ATM IV 319.80%), the computed maximum profit is unbounded per contract and the computed maximum loss is unbounded per contract. Live intraday quotes will differ as the chain moves through the trading session.
- What is the breakeven for a GYRE long call?
- The breakeven for the GYRE long call priced on this page is no defined breakeven on the modeled curve at expiration, derived from end-of-day chain premiums. Breakeven is the underlying price at which the strategy's P&L crosses zero ignoring transaction costs and assignment risk. The current GYRE market-implied 1-standard-deviation expected move is approximately 91.68%; if the move sits well outside the breakeven distance, the structure's risk-reward becomes correspondingly tighter.
- When should you consider a long call on GYRE?
- Long calls on GYRE express a bullish thesis with defined risk; traders use them ahead of GYRE catalysts (earnings, product launches, macro events) when the expected upside justifies the premium and theta decay.
- How does current GYRE implied volatility affect this long call?
- GYRE ATM IV is at 319.80% with IV rank near 63.64%, which is mid-range against its 1-year history. Strategy selection depends more on directional thesis and expected move than on a strong IV signal.